Previous close | 1.7500 |
Open | 1.7500 |
Bid | 1.8000 |
Ask | 2.0000 |
Strike | 7.00 |
Expiry date | 2025-01-17 |
Day's range | 1.7500 - 1.7500 |
Contract range | N/A |
Volume | |
Open interest | 4.32k |
ROCKVILLE, Md. & EDMONTON, Alberta, June 05, 2024--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced an oral presentation at the European Alliance of Associations for Rheumatology (EULAR) 2024 taking place in Vienna, Austria June 12-15. The data reinforces previous findings from the AURORA Clinical Program on the safety and effectiveness of LUPKYNIS® (voclosporin), a second generation calcineurin inhibitor (CNI), for the treatment of adult patients with active
ROCKVILLE, Md. & EDMONTON, Alberta, June 04, 2024--Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
ROCKVILLE, Md. & EDMONTON, Alberta, June 03, 2024--Aurinia Provides Update on Proxy Statement